E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10018292 |
E.1.2 | Term | Gingivitis |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate and compare gingivitis as measured by Modified Gingival Index (MGI) and Bleeding Index (BI) following twice daily use of an experimental toothpaste compared to a reference toothpaste after 12 weeks |
|
E.2.2 | Secondary objectives of the trial |
To evaluate and compare gingivitis as measured by MGI and BI following twice daily use of experimental toothpaste compared to reference toothpaste after 4 and 8 weeks.
To evaluate and compare dental plaque scores (overall and interproximal) following twice daily use of experimental toothpaste compared to reference toothpaste after 4, 8 and 12 weeks.
To evaluate and compare changes in cultivable plaque bacterial groups in plaque samples, following twice daily use of experimental toothpaste compared to reference toothpaste after 4 and 12 weeks
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Consent Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form. 2. Age Aged at least 18 years. 3. Compliance Understands and is willing, able and likely to comply with all study procedures and restrictions. 4. General Health Good general health in the opinion of the investigator, with no clinically significant and relevant abnormalities of medical history or physical examination. 5. Dental Health a) A minimum of 20 permanent gradable teeth. A scorable surface is defined as a surface that has 50% of the surface gradable. Third molars, orthodontically banded/ bonded, fully crowned or extensively restored, grossly carious or abutment teeth are not included in the tooth count. b) Mild to moderate gingivitis present at the screening visit in the opinion of the investigator. c) MGI between 1.50 and 2.30 at Pre-Prophy Baseline and Randomisation visit. d) Reduction in MGI between Pre-Prophy Baseline and Randomisation visit. e) All teeth required for plaque sampling are present (for sub-set of subjects undergoing plaque sampling only).
|
|
E.4 | Principal exclusion criteria |
1. Pregnancy Women who are known to be pregnant or who are intending to become pregnant over the duration of the study. 2. Breast-feeding Women who are breast–feeding. 3. Allergy/Intolerance Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients. 4. Dental Health a) Have current active caries or periodontitis that may compromise the study or the health of the subjects in the opinion of the investigator or MGI examiner. b) Restorations in a poor state of repair. c) Partial dentures or orthodontic appliances. 5. Smokers Current smokers or smokers who have quit within the past 6 months prior to screening. 6. Medication a) Currently taking antibiotics or have taken antibiotics in the 2 weeks prior to gingival health examinations. b) Use of any systemic medication which would have an effect on gingival conditions within 14 days of gingival health examinations (e.g. calcium channel blockers, ibuprofen or aspirin therapy). 7. Clinical Study/Experimental Medication a) Participation in another clinical study or receipt of an investigational drug within 30 days of the screening visit. b) Previous participation in this study. 8. Substance abuse Recent history (within the last year) of alcohol or other substance abuse. 9. Personnel a) An employee of the sponsor or the study site or members or their immediate family. b) An employee of any toothpaste manufacturer or their immediate family.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
A cosmetic toothpaste containing Sodium Fluoride, but no Isopropylmethylphenol |
|
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 84 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |